insights_auto
Por qué ha bajado OPHLY 2,31%?
Profundizarchevron_right
OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
4,65 US$
arrow_downward
-2,31%(-0,11) 1 d
14 oct, 16:00:00 GMT-4 · USD
search
Todos los símbolos
| Símbolo | Precio | Cambio | % de cambio |
|---|
insights_autoGenerando estadísticas principales de OPHLY...
Abrir
4,71 US$
Alto
4,93 US$
Bajo
4,63 US$
Cap. burs.
1,13 B
Vol. medio
62,09 mil
Volumen
35,04 mil
Máximo en 52 sem.
5,75 US$
Mínimo en 52 sem.
3,82 US$
Beta
0,21
Acciones en circulación
1496,23 M
N.º de empleados
4 mil
Abrir
4,71 US$
Alto
4,93 US$
Bajo
4,63 US$
Cap. burs.
1,13 B
Vol. medio
62,09 mil
Volumen
35,04 mil
Máximo en 52 sem.
5,75 US$
Mínimo en 52 sem.
3,82 US$
Beta
0,21
Acciones en circulación
1496,23 M
N.º de empleados
4 mil
Noticias
De fuentes web y partners de noticias
es.qz.com
·
hace 10 horas
Futuros de Dow suben antes del informe del IPC de septiembre y los ganancias del tercer trimestre de bancos.
El Ecosistema Startup
·
hace 14 horas
S&P 500: IA impulsa 34% de crecimiento en ganancias
MarketScreener España
·
hace 3 horas
El Nasdaq y el S&P 500 encadenan su tercera sesión a la baja tras un dato de IPC superior a lo previsto
Perfil
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Acerca de Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
CEOGyo Sagara | Gyo Sagara
Empleados4,21 mil
Fundación1717
SedeOsaka, Prefectura de Osaka, Japón
Sector-
Sitio webono-pharma.com